- Home
- NMFC vs AQST Comparison
NMFC vs AQST Comparison
Compare NMFC & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMFC
- AQST
- Stock Information
- Founded
- NMFC 2010
- AQST 2004
- Country
- NMFC United States
- AQST United States
- Employees
- NMFC N/A
- AQST N/A
- Industry
- NMFC Finance/Investors Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NMFC Finance
- AQST Health Care
- Exchange
- NMFC Nasdaq
- AQST Nasdaq
- Market Cap
- NMFC 972.8M
- AQST 809.3M
- IPO Year
- NMFC 2011
- AQST 2018
- Fundamental
- Price
- NMFC $9.56
- AQST $6.01
- Analyst Decision
- NMFC Hold
- AQST Strong Buy
- Analyst Count
- NMFC 4
- AQST 7
- Target Price
- NMFC $10.00
- AQST $10.00
- AVG Volume (30 Days)
- NMFC 607.2K
- AQST 3.0M
- Earning Date
- NMFC 11-03-2025
- AQST 11-05-2025
- Dividend Yield
- NMFC 13.52%
- AQST N/A
- EPS Growth
- NMFC N/A
- AQST N/A
- EPS
- NMFC 0.66
- AQST N/A
- Revenue
- NMFC $340,877,000.00
- AQST $43,397,000.00
- Revenue This Year
- NMFC N/A
- AQST N/A
- Revenue Next Year
- NMFC N/A
- AQST $51.39
- P/E Ratio
- NMFC $14.42
- AQST N/A
- Revenue Growth
- NMFC N/A
- AQST N/A
- 52 Week Low
- NMFC $8.84
- AQST $2.12
- 52 Week High
- NMFC $12.05
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- NMFC 54.33
- AQST 52.24
- Support Level
- NMFC $8.98
- AQST $5.53
- Resistance Level
- NMFC $9.24
- AQST $6.17
- Average True Range (ATR)
- NMFC 0.19
- AQST 0.43
- MACD
- NMFC 0.00
- AQST 0.00
- Stochastic Oscillator
- NMFC 71.34
- AQST 53.66
About NMFC New Mountain Finance Corporation
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.